Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
摘要:
The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
申请人:CEPHALON INC
公开号:WO2010071885A1
公开(公告)日:2010-06-24
The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
The present invention provides a compound of formula I
or a salt form thereof, wherein Q
1
, Q
2
, Q
3
, and Q
4
are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
作者:Craig A. Zificsak、Diane E. Gingrich、Henry J. Breslin、Derek D. Dunn、Karen L. Milkiewicz、Jay P. Theroff、Tho V. Thieu、Ted L. Underiner、Linda R. Weinberg、Lisa D. Aimone、Mark S. Albom、Jennifer L. Mason、Lisa Saville、Jean Husten、Thelma S. Angeles、James P. Finn、Mahfuza Jan、Teresa M. O’Kane、Pawel Dobrzanski、Bruce D. Dorsey
DOI:10.1016/j.bmcl.2011.11.049
日期:2012.1
The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression. (C) 2011 Elsevier Ltd. All rights reserved.
Pyrrolotriazines as ALK and JAK2 inhibitors
申请人:Breslin Henry J.
公开号:US08471005B2
公开(公告)日:2013-06-25
The present invention provides a compound of formula I
or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.